Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s share price fell 0.4% during mid-day trading on Friday after BMO Capital Markets lowered their price target on the stock from $160.00 to $156.00. BMO ...

Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging ...

Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...

CVS announced Friday that CEO Karen Lynch will be replaced by David Joyner, as consumer spending drops at the company's retail pharmacies and Aetna, its insurance unit, faces higher medical costs.

Novo Nordisk announced the European Medicines Agency's CHMP has adopted a positive opinion, recommending approval of Alhemo as the ...

Novo Nordisk's Alhemo drug has been recommended for European approval as a treatment for hemophilia, the company said Friday.